Effects of Microencapsulated Propolis and Turmeric in Patients With Chronic Kidney Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

Microcapsules with turmeric and propolis: Participants will receive microcapsules containing 0.250 milligrams of turmeric 95% curcumin and 0.250 milligrams of green propolis, twice a day for 12 weeks

Study summary

Oxidative stress and inflammation are correlated with Chronic Kidney Disease (CKD), in a way that they bring several harms to patients, including an increased risk of cardiovascular disease and mortality. Adjuvant therapeutic options such as bioactive compounds present in some foods seem to mitigate inflammation. Turmeric and propolis are foods that have compounds with antioxidant and anti-inflammatory capacity, as they promote the activation of nuclear erythroid transcription factor 2 (Nrf2 - responsible for the synthesis of antioxidant enzymes) and inhibit the activity of nuclear factor Kappa B (NF-κB - which increases the synthesis of inflammatory cytokines). This work aims to evaluate the effects of supplementation of associated propolis and turmeric microcapsules on inflammatory markers in patients with CKD undergoing hemodialysis (HD).

Eligibility

Primary outcome measure(s)

• The effects of the supplementation on the expression of transcription factors — 4 months
  Obtain blood samples to assess the effects of supplementation on biomarkers related to inflammation and antioxidant capacity, such as: erythroid nuclear transcription factor 2 (Nrf2) and nuclear factor Kappa B (NF-κB)
• The effects of the supplementation on inflammatory cytokines — 4 months
  Get blood samples to evaluate the supplementation effects on cytokines (IL-6, TNF-α)

Trial sites (1)

More Universidade Federal Fluminense trials in Brazil

Other trials for the same condition